Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer

Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer

Abstract Members of the human epidermal growth factor receptor (HER) family play a significant role in bladder cancer progression and may underlie the development of chemotherapy resistance. Dacomitinib is an irreversible tyrosine kinase inhibitor with structural specificity for the catalytic domain...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Petros D. Grivas, Kathleen C. Day, Andreas Karatsinides, Alyssa Paul, Nazia Shakir, Iya Owainati, Monica Liebert, Lakshmi P. Kunju, Dafydd Thomas, Maha Hussain, Mark L. Day
التنسيق: مقال
اللغة:English
منشور في: BMC 2013-10-01
سلاسل:Molecular Medicine
الموضوعات:
Dacomitinib
Bladder Cancer Xenografts
Non-obese Diabetic/severe Combined Immunodeficiency (NOD/SCID)
Epidermal Growth Factor Receptor (EGFR)
Lapatinib
الوصول للمادة أونلاين:https://doi.org/10.2119/molmed.2013.00108

الانترنت

https://doi.org/10.2119/molmed.2013.00108

مواد مشابهة